Synthetic Peptide Melanoma Vaccine

For this article, Eugene Russo interviewed Steven A. Rosenberg, chief of surgery at the National Cancer Institute. Data from the Web of Science (ISI, Philadelphia) show that this paper has been cited significantly more often than the average paper of the same type and age. S.A. Rosenberg, J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, D.E. White

Eugene Russo
Feb 20, 2000

For this article, Eugene Russo interviewed Steven A. Rosenberg, chief of surgery at the National Cancer Institute. Data from the Web of Science (ISI, Philadelphia) show that this paper has been cited significantly more often than the average paper of the same type and age.

S.A. Rosenberg, J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, D.E. White, "Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma," Nature Medicine, 4:321-7, March 1998. (Cited in more than 170 papers since publication)

This paper translated years of molecular data on the immune system into tangible human clinical trial results. National Cancer Institute chief of surgery Steven A. Rosenberg and his colleagues had been trying to develop new cancer immunotherapies for more than 15...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?